Routine Evaluation of People Living With Cancer
People with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group. As cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. This altered state of illness can have m
| Condition(s) | Cachexia; Cancer, Advanced Cancer, Quality of Life |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | People with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group. As cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. This altered state of illness can have multiple ill effects including weight loss, fatigue, increased symptom burden and reduction in physical function which all contribute to a reduced quality of life. These areas are often studied in isolation, giving an incomplete picture. A detailed, holistic characterisation of this group of people does not exist. A robust characterisation of people with incurable cancer will allow identification and prioritisation of future research and has the potential to inform new therape |
| Who can participate | Inclusion Criteria: * Patients with incurable cancer (metastatic cancer (Clinical, histological, cytological or radiological evidence) or receiving anti-cancer therapy with palliative intent). * Aged 18-years and over * Written informed consent Exclusion Criteria: * Any concomitant medical or psychiatric problems which, in the opinion of the investigator, would increase the risk of complication for the participant and/or investigator. * Participants will not be able to take part in bio-impedance analysis if they have a pacemaker or implantable cardiac defibrillator. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Edinburgh |
| Locations | Edinburgh, United Kingdom |
| Start date | 2020-07-15 |
| NCT ID | NCT04406662 |
| Official listing | https://clinicaltrials.gov/study/NCT04406662 |